Factor Bioscience to Deliver Four Presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting

On May 16, 2022 Factor Bioscience Inc., a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies, reported its participation in the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 25th Annual Meeting to be held in Washington, D.C. from May 16-19, 2022, at which Factor will deliver four presentations (Press release, Factor Bioscience, MAY 16, 2022, View Source;cell-therapy-asgct-25th-annual-meeting-301547566.html [SID1234614684]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

iPSC-Derived Monocytes Generate Functional M1 and M2 Macrophages with Enhanced Cytokine Secretion and Tumor Cell-Killing Activity
iPSC-Derived Monocytes Generate Functional M1 and M2 Macrophages with Enhanced Cytokine Secretion and Tumor Cell-Killing Activity
Factor to reveal mRNA-based iPS cell-derived macrophages for solid-tumor targeting

"iPSC-Derived Monocytes Generate Functional M1 and M2 Macrophages with Enhanced Cytokine Secretion and Tumor Cell-Killing Activity." -to be presented by Ian Hay on May 18 at 5:00 pm, Engineered Cell Therapies Oral Abstract Session, Room 206.

"Cytotoxic Lymphocytes Derived from B2M-Knockout iPSCs Show Enhanced Expansion and Cytokine-Controlled Cytotoxicity In Vitro." -to be presented by Mackenzie Parmenter on May 17 from 5:30-6:30 pm, Cell Therapies II Poster Session.

"The Immunosuppressive TTAGGG Motif Improves Homology-Directed Insertion of DNA Sequences in Human Primary and Induced Pluripotent Stem (iPS) Cells." -to be presented by Abigail Blatchford on May 17 from 5:30-6:30 pm, Oligonucleotide Therapeutics II Poster Session.

"Resveratrol Treatment Increases Homology-Directed Repair in Primary Human Cells." -to be presented by Taeyun Kim on May 18 from 5:30-6:30 pm, Gene Targeting and Gene Correction III Poster Session.
Digital presentations will be made available on the ASGCT (Free ASGCT Whitepaper) website on May 16, 2022. For more information about the American Society of Genetic & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting, visit View Source